Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) have earned an average recommendation of “Buy” from the seven brokerages that are covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued a report on the stock in the last year is $8.80.
Several brokerages have commented on PYXS. Royal Bank of Canada restated an “outperform” rating and set a $7.00 target price on shares of Pyxis Oncology in a research report on Friday, March 22nd. Jefferies Financial Group restated a “buy” rating and set a $10.00 target price on shares of Pyxis Oncology in a research report on Tuesday, May 7th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a research report on Thursday, May 16th.
View Our Latest Report on PYXS
Institutional Investors Weigh In On Pyxis Oncology
Pyxis Oncology Stock Performance
Shares of PYXS opened at $3.38 on Friday. The stock has a market capitalization of $199.05 million, a P/E ratio of -2.49 and a beta of 1.33. The company’s fifty day moving average is $4.10 and its two-hundred day moving average is $3.88. Pyxis Oncology has a 1 year low of $1.35 and a 1 year high of $6.85.
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last announced its quarterly earnings data on Saturday, May 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.19. The firm had revenue of $16.15 million during the quarter, compared to analyst estimates of $4.25 million. Sell-side analysts predict that Pyxis Oncology will post -1.09 EPS for the current year.
Pyxis Oncology Company Profile
Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
See Also
- Five stocks we like better than Pyxis Oncology
- Retail Stocks Investing, Explained
- Darden Stock Up After Q4 Earnings Beat, Cautious FY25 Outlook
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Celsius Stock: Why Piper Sandler Forecasts a 50% Surge
- Roth IRA Calculator: Calculate Your Potential Returns
- Accenture’s Stock Earnings Reveal an AI-Powered Growth Strategy
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.